Senna; Docusate

What it is

This is a fixed over-the-counter combination of two different laxatives in one tablet. The stimulant component is sennosides, the anthraquinone glycosides extracted from the senna plant, standardised to 8.6 mg per tablet in the common product. The softener component is docusate sodium, an anionic surfactant, at 50 mg per tablet. Both are sold separately as well, and because they are separate molecules with separate trials, the evidence below is reported component by component before the combination.

What the research says

The two halves have very different evidence. Senna works: a placebo-controlled randomised trial in chronic constipation found overall improvement in 69.2% on senna versus 11.7% on placebo. Docusate largely does not: a review of the randomised trials in older people concluded that docusate compared with placebo, psyllium or sennosides showed no benefit, and a double-blind trial in hospice patients found adding docusate to sennosides was no better than adding placebo. For the fixed combination specifically, in palliative care a Cochrane review found no evidence that any one laxative was more effective than another, and for opioid-induced constipation a systematic review found no trials at all that met its inclusion criteria. The widely held belief that stimulant laxatives are habit-forming or damage the bowel is not supported by the literature.

Evidence grade: Limited evidence.

How it works

Drug class: Fixed combination laxative: an anthraquinone (anthranoid) stimulant laxative, sennosides from Senna alexandrina, with an anionic surfactant stool softener, docusate sodium

Senna is a stimulant: sennosides act locally on the nerve plexus and smooth muscle of the intestine to increase movement and secretion. Docusate is a detergent: it lowers the surface tension at the water-oil interface of the stool so that water and fat mix into it, which softens the stool and is meant to reduce straining. The combination pairs a push with a softener. (Source 1)

What it is used for

• This is the labelled use, and the label itself limits it: not longer than one week without a doctor's direction. The senna component has placebo-controlled randomised evidence behind it; the docusate component does not, and no trial we found tested the fixed combination against senna alone for occasional constipation. Evidence: limited. (Source 2)
• A 28-day double-blind randomised placebo-controlled trial of 90 patients found senna clearly better than placebo for overall improvement, bowel movement frequency and quality of life, and similar to magnesium oxide. It is one small trial of mostly women at a single setting, and it is off-label because the over-the-counter label covers occasional constipation only. Evidence: limited. (Source 3)
• A Cochrane review identified five small randomised trials covering lactulose, senna, co-danthramer, misrakasneham, docusate and magnesium hydroxide with liquid paraffin. Because every trial compared different agents, no meta-analysis was possible and the review found no evidence that any one laxative was more effective or safer than another. Evidence: limited. (Source 4)
• A systematic review set out to compare docusate sodium, sennosides and lactulose against polyethylene glycol in opioid-induced constipation and found that no studies met its inclusion criteria, so statistical pooling was not possible. That is an absence of evidence, not evidence of absence of effect. Evidence: unknown. (Source 5)
• Docusate sodium is licensed as a stool softener, but the randomised evidence does not support it. A review of four randomised trials in older people found no benefit against placebo, psyllium or sennosides, and a double-blind placebo-controlled hospice trial found no significant benefit of adding docusate to sennosides. Evidence: not-supported. (Source 6)
• A systematic review of seven randomised trials in 444 long-term care patients found senna superior to or as effective as other laxatives, with similar adverse drug reaction rates between arms and no serious reactions reported. The authors say the short trial duration and the low quality of some trials leave long-term efficacy and safety unresolved. Evidence: limited. (Source 7)
• A Cochrane review found only two studies contributing data, 180 women in total. Compared with bulk-forming laxatives, stimulant laxatives improved constipation more (risk ratio 1.59) but caused more abdominal discomfort and more diarrhoea, with no difference in women's satisfaction. The over-the-counter label simply says to ask a health professional first. Evidence: limited. (Source 8)

Interactions

• Mineral oil (liquid paraffin) (label): This is the one interaction printed on the label, and it belongs to the docusate half. Docusate is a surfactant, so it can help mineral oil cross the gut wall rather than stay in the bowel. The Drug Facts panel instructs users not to take docusate if they are presently taking mineral oil unless told to by a doctor. (Source 9)
• Absorption of other medicines taken by mouth (label): Readers often expect that a laxative will wash other tablets through before they are absorbed. We should be honest that we could not substantiate this for senna or docusate: the Drug Facts panels of all three products we parsed name only mineral oil, and we found no pharmacokinetic study of senna or docusate reducing the absorption of another medicine. Searches of Europe PMC for laxatives with drug absorption or bioavailability returned nothing on these two agents. What is documented is the mineral-oil instruction, which runs the other way: docusate may increase absorption of something that is meant to stay in the gut. (Source 9)
• Diuretics and other medicines or conditions that lower potassium (case reports): Laxatives can lower blood potassium, and the systematic review of case reports named drug-drug and drug-disease interactions, non-potassium electrolyte imbalance and herbal laxatives among the contributing factors in 27 reported cases of hypokalaemic cardiac toxicity, two of them fatal. All of these were case reports and most involved doses above those recommended. (Source 10)
• Fibre supplements such as Plantago ovata (psyllium) (clinical trial): Senna has been studied both with and without fibre in long-term care trials, and psyllium was one of the comparators that outperformed docusate. This is co-use in trials rather than a documented adverse interaction: no harm from combining them was reported. (Source 7)
• Alcohol (theoretical): We found no documented interaction between senna or docusate and alcohol: it appears in none of the three Drug Facts panels we parsed and in none of the reviews or trials we read. What the stimulant laxative review does say about side-effect risk at recommended doses is that the risk of dehydration or electrolyte disturbance is negligible, and that the commonest electrolyte problem, low potassium, is associated with misuse, abuse or colon cleansing rather than labelled use. Heavy drinking causes dehydration and poor potassium status by its own routes, so the plausible concern is additive, not documented. Limit: Sanofi funded this review's publication costs and medical writing and one co-author is a Sanofi employee; Sanofi markets stimulant laxatives. The same paragraph goes on to state the other side - that safety concerns have been raised about long-term stimulant laxative use, that some studies indicate structural damage to epithelial cells, the myenteric plexus and intestinal smooth muscle, and that colon cancer has been speculated about. The inline numbers ("is negligible. 11") are reference numbers, not data. (Source 1)
• Food and meal timing (label): Neither label conditions the dose on food. What the labels do say about timing is that senna is preferably taken at bedtime, which matches its 6 to 12 hour onset, and docusate may be taken as a single daily dose or in divided doses and only by mouth. (Source 11)

Stopping it

• The belief that laxatives are habit-forming is the single most common misconception about them, and the literature does not support it. The clearest published statement is that tolerance to stimulant laxatives is uncommon, that there is no indication of rebound constipation after stopping, and that there is no potential for addiction. Some people with chronic constipation do depend on laxatives to have satisfactory bowel function, but that dependence is attributed to their underlying condition rather than to having taken laxatives. (Source 12)
• The related fear, that long-term use wears out the bowel, also lacks support. A 2024 review of 43 publications concluded that no well-controlled prospective clinical study has shown structural damage to enteric nerves or intestinal smooth muscle at recommended therapeutic doses, and that cathartic colon is a historical entity: the 41 alleged cases came from patients who started laxatives between 1910 and 1960, with none published since. That review was funded by a laxative manufacturer, which is a reason to weigh it carefully rather than dismiss it. (Source 13)
• One documented change does reverse on stopping. Melanosis coli, the dark pigmentation of the colon lining that follows long-term senna use, disappeared on repeat colonoscopy seven months after one patient stopped a five-year course. That is a single case, and the report's own point is that how long this takes in general is not well understood. (Source 14)
• The labels themselves set a stopping rule that has nothing to do with dependence: do not use laxative products for longer than one week unless a doctor directs it, and for docusate, needing a stool softener for more than one week is itself a reason to stop and ask. Rectal bleeding, or failing to have a bowel movement after using a laxative, are stop-and-ask-a-doctor signals in both panels because they may indicate a serious condition. (Source 15)
• The docusate Drug Facts panel also carries the standard over-the-counter overdose instruction, which is about what to do rather than about stopping: keep the product out of reach of children, and in case of overdose get medical help or contact a Poison Control Center right away. (Source 16)

What goes wrong

Laxative-induced low blood potassium has caused serious cardiac toxicity, including two deaths, in published case reports. (Source 10)

• Systematic review, Very low certainty.
• Size: 27 incidents in 12 countries reported between 1995 and 2019.
• Who: 19 female and 8 male patients, ages ranging from 1 month to 93 years.
• How long: case reports over 23 years.
• Result: severe hypokalaemia in 48% of cases, moderate in 44.4%, mild in 7.4%; typical hypokalaemic electrographic changes in 70%, abnormal cardiac rhythm in 7.4%, very serious cardiotoxicity in 18.5%; two patients died.
• Funding: not stated in the abstract.

Limit of this finding: The three cardiac-effect categories sum to 95.9%, not 100%, so the sub-counts do not account for every case and a reader should not treat 18.5% as a rate of very serious toxicity among laxative users generally. Case reports have no denominator, and the review names non-adherence to the recommended dose and laxative abuse among the contributing factors, so these are not events at labelled use. The review also contradicts its own search period: the passage says "Over the 23 years" while its methods give the search as 1995 to 2019. And 70% of 27 cases is 19 cases (70.4%), so the printed 70% is rounded.

In 70% of patients, the effect of laxative on the heart was typical hypokalaemic electrographic changes, 7.4% showed abnormal changes in cardiac rhythm, whereas in 18.5%, the cardiotoxicity observed was a very serious kind. Two patients died due to severe cardiac effects.

In a single case report, melanosis coli found during five years of senna use was no longer visible at colonoscopy seven months after the senna was stopped. (Source 14)

• Case report, Very low certainty.
• Size: 1 patient.
• Who: an 81-year-old woman who had taken senna laxatives for 5 years.
• How long: 5 years of use; colonoscopy 7 months after stopping.
• Result: melanosis coli diagnosed on colonoscopy during use; no melanosis coli visible at colonoscopy 7 months after cessation.
• Funding: not stated in the abstract.

Limit of this finding: A single case report cannot establish how often melanosis coli occurs or how long it takes to clear in general; the report's own point is that the duration of improvement after stopping is not well understood.

We describe the case of an 81-year-old female diagnosed with melanosis coli via colonoscopy who had been taking senna laxatives for 5 years. Seven months after cessation of senna laxatives, colonoscopy showed no melanosis coli in the colon.

Senna has been linked to liver injury in case reports, including a biopsy-confirmed subacute cholestatic hepatitis that resolved after stopping. (Source 17)

• Case report, Very low certainty.
• Size: 1 patient.
• Who: a 77-year-old man with chronic senna intake for chronic constipation.
• How long: chronic intake; slow recovery after withdrawal.
• Result: abdominal pain, jaundice and raised transaminases; liver biopsy showed bridging hepatocellular necrosis and canalicular cholestasis; drug withdrawal produced a slow progressive fall in bilirubin and liver enzymes.
• Funding: not stated in the abstract.

Limit of this finding: One patient, and the source itself hedges - "likely related" in the title, "senna was likely the cause" in the text - so this establishes a possible association only. The patient was also hepatitis B surface antigen positive, which the authors read as healthy-carrier status, and had already had a sphincterotomy for suspected extrahepatic cholestasis before the senna history emerged. We could not reach the NIH LiverTox senna monograph, which was serving a CAPTCHA, so we cannot say how many such cases are catalogued.

Further interrogation of the patient revealed a history of chronic senna intake to treat a chronic constipation. Liver biopsy showed bridging hepatocellular necrosis as well as canalicular cholestasis. Drug withdrawal resulted in a slow and progressive reduction in bilirubin levels and liver enzymes. In this case senna was likely the cause of a subacute cholestatic hepatitis exemplifying again the potential role of herbal related liver injury.

In pregnancy, stimulant laxatives improved constipation more than bulk-forming laxatives but caused more abdominal discomfort and more diarrhoea. (Source 8)

• Systematic review, Moderate certainty.
• Size: 4 studies included but only 2 contributing data, 180 women; the stimulant comparison rests on 140 women in one study.
• Who: pregnant women with constipation.
• How long: not stated in the abstract.
• Result: improvement in constipation risk ratio 1.59, 95% CI 1.21 to 2.09 (moderate quality); abdominal discomfort risk ratio 2.33, 95% CI 1.15 to 4.73 (low quality); diarrhoea risk ratio 4.50, 95% CI 1.01 to 20.09 (moderate quality); women's satisfaction risk ratio 1.06, 95% CI 0.77 to 1.46.
• Funding: Cochrane review; funding not stated in the abstract.

Limit of this finding: Every figure here comes from a single study of 140 women whose randomisation method was unclear. The review's results section calls the diarrhoea finding a "borderline difference" (risk ratio 4.50, 95% CI 1.01 to 20.09) while its own conclusions call it "an increase in diarrhoea" - two readings of one estimate whose upper bound is a twentyfold risk. The authors' "insufficient evidence" sentence sits outside this block and is quoted separately in rungsiprakarn-2015-conclusions, which is the finding that should be read beside this one.

Compared to bulk-forming laxatives, pregnant women who received stimulant laxatives had significantly more improvement in constipation (risk ratio (RR) 1.59, 95% confidence interval (CI) 1.21 to 2.09; 140 women, one study, moderate quality of evidence), but also significantly more abdominal discomfort

The over-the-counter labels themselves limit use to one week and list the symptoms that should stop it, which is the clearest harm signal a user will actually see. (Source 18)

• Official position, Certainty not rated.
• Size: not applicable.
• Who: people buying senna or senna with docusate over the counter.
• How long: the label's own limit is 1 week without medical direction.
• Result: no rates given; the Drug Facts panel instructs users not to take laxative products for longer than 1 week unless directed by a doctor, and to stop and ask a doctor for rectal bleeding or failure to have a bowel movement.
• Funding: regulator-approved product label (a position, dated 2026)

Do not use laxative products for longer than 1 week unless directed by a doctor

Before any use, the docusate Drug Facts panel directs anyone with stomach pain, nausea, vomiting, or a sudden change in bowel habits lasting more than two weeks to ask a doctor first. (Source 19)

• Official position, Certainty not rated.
• Size: not applicable.
• Who: anyone buying the product over the counter.
• How long: before use.
• Result: no rates given; the panel lists four symptoms that must be checked with a doctor before the product is taken.
• Funding: regulator-approved product label (a position, dated 2026)

Limit of this finding: These four symptoms are the screen for a possible bowel obstruction or other serious cause, which a laxative could make worse. The panel gives no frequencies, so this is a label position and not a measure of how often harm occurs.

Ask a doctor before use if you have stomach pain nausea vomiting noticed a sudden change in bowel habits that lasts over 2 weeks

What the evidence supports

Senna improved chronic constipation far more than placebo in a double-blind randomised trial, and as much as magnesium oxide. (Source 3)

• Randomized trial, Low certainty.
• Size: 90 patients, all of whom completed the study.
• Who: patients with chronic idiopathic constipation, mean age 42 years, 93% women, mean symptom duration 9.9 years.
• How long: 28 consecutive days.
• Result: response rate for overall improvement 11.7% placebo, 69.2% senna, 68.3% magnesium oxide, P < 0.0001; an absolute difference of 57.5 percentage points for senna over placebo, number needed to treat about 2; change in spontaneous bowel movements significantly greater than placebo, P < 0.001; severe treatment-related adverse events 0%.
• Funding: not stated in the abstract.

Limit of this finding: Ninety patients, 93% of them women, in a single 28-day study; the three arms are described with one overall P value rather than pairwise comparisons, so the senna-versus-magnesium-oxide equivalence is not formally tested. The abstract never gives per-arm denominators, and the three response rates (11.7%, 69.2%, 68.3%) cannot come from three equal arms of 30, where any rate must be a multiple of about 3.3%. They are consistent with pooling over the four assessment weeks (14, 83 and 82 out of 120). Until the full text is checked these must not be shown as "x people in 30".

The response rate for overall improvement was 11.7% in the placebo group, 69.2% in the senna group, and 68.3% in the MgO group (P < 0.0001). Change in SBM was significantly greater in the senna and MgO groups than that in the placebo group (P < 0.001). Similarly, change in complete SBM was significantly greater in the senna and MgO groups than that in the placebo group (P < 0.01).

Senna was superior to or as effective as other laxatives in long-term care residents, with similar adverse reaction rates across arms. (Source 7)

• Systematic review, Low certainty.
• Size: 7 randomised trials involving 444 patients.
• Who: long-term care patients with chronic constipation.
• How long: short trials; the review states that long-term efficacy and safety are not conclusive.
• Result: no pooled effect size given; the review reports senna as superior to or as effective as other laxatives and similar adverse drug reaction frequency and severity between arms, with no serious reactions reported.
• Funding: not stated in the abstract.

Limit of this finding: Seven short trials in 444 residents with no meta-analysis and no pooled numbers. The review's own conclusion is that long-term efficacy and safety are not conclusive and that more robust trials including newer agents are needed.

Senna and lactulose were the most studied laxatives in LTC patients, and senna was found to be superior to or as effective as other laxatives. Generally, the frequency and severity of adverse drug reactions (ADRs) were similar between the arms of the studies, and no serious ADRs were reported.

Stimulant and non-stimulant laxatives both relieved constipation better than placebo, and all studies reported minor side effects regardless of treatment duration. (Source 20)

• Systematic review, Low certainty.
• Size: 19 clinical studies and 4 meta-analyses.
• Who: adults and children with functional constipation, with emphasis on studies using Rome criteria.
• How long: one week to one year.
• Result: no pooled effect sizes reported in the abstract; the review states both classes beat placebo on objective and subjective measures, that only one study compared a non-stimulant with a stimulant, and that all studies reported minor side effects.
• Funding: not stated in the abstract.

Limit of this finding: The review's stated scope is the pharmacological laxatives commercially available in Canada, with emphasis on studies using the Rome criteria, so "both nonstimulant and stimulant laxatives" means that set and not laxatives in general. Only one of the 19 studies compared a nonstimulant against a stimulant and only two reported quality of life, so the review cannot support any preference between the two classes. Most of the studies concerned polyethylene glycol rather than senna or docusate.

Both nonstimulant and stimulant laxatives provided better relief of constipation symptoms than placebo according to both objective and subjective measures. Only one study compared the efficacy of a nonstimulant versus a stimulant laxative, while only two reported changes in quality of life. All studies reported minor side effects due to laxative use, regardless of treatment duration, which ranged from one week to one year. Laxatives were well tolerated by both adults and children.

What the evidence does not support

Adding docusate to sennosides was no better than adding placebo to sennosides in hospice patients. (Source 21)

• Randomized trial, Moderate certainty.
• Size: 74 patients randomised (35 docusate, 39 placebo)
• Who: hospice patients in Edmonton aged 18 or over, able to take oral medication, Palliative Performance Scale 20% or more.
• How long: 10 days.
• Result: no significant differences between groups in stool frequency, volume or consistency, nor in difficulty or completeness of evacuation; the only significant difference was in the distribution of Bristol Stool Form types (P=0.01), which went in the direction of softer stool on placebo.
• Funding: not stated in the abstract.

Limit of this finding: The abstract contradicts itself here: it says there were no significant differences between the groups in stool consistency and then reports a statistically significant between-group difference on the Bristol Stool Form Scale (P=0.01), which is a measure of stool consistency. Both arms received sennosides, so the comparison is docusate added to sennosides against placebo added to sennosides - it says nothing about docusate against no laxative at all.

There were neither significant differences between the groups in stool frequency, volume, or consistency, nor in difficulty or completeness of evacuation. On the Bristol Stool Form Scale, more patients in the placebo group had Type 4 (smooth and soft) and Type 5 (soft blobs) stool, whereas in the docusate group, more had Type 3 (sausage like) and Type 6 (mushy) stool (P=0.01).

A review of the randomised trials found docusate gave no benefit for constipation in older people against placebo, psyllium or sennosides. (Source 6)

• Expert review, not systematic, Low certainty.
• Size: 4 studies describing docusate for chronic or general constipation in older people.
• Who: older adults with chronic or general constipation.
• How long: not stated in the abstract.
• Result: no pooled effect size; the review reports no benefit of docusate over placebo and that psyllium and sennosides were more effective than docusate.
• Funding: not stated in the abstract.

Limit of this finding: Four studies, found by a single-database PubMed search by one author, with no pooled estimate, effect size, confidence interval or p-value anywhere in the source - so there is no number here on which a quantitative claim could rest. The design is recorded as a narrative review rather than a systematic review for that reason. The phrases "there is a lack of data to support the use of docusate" and "docusate is not effective" sit in the same paragraph and are not the same claim.

Docusate when compared with placebo or psyllium or sennosides in these trials did not show any benefits for constipation. Psyllium and sennosides showed to be more effective compared with docusate. No differences found between docusate versus placebo. In summary, there is a lack of data to support the use of docusate for constipation and the data presented that docusate is not effective for use in constipation.

A Cochrane review of laxatives in palliative care found no evidence that any one laxative, including senna or docusate, was more effective or safer than another, and warned against reading across from trials in other populations. (Source 4)

• Systematic review, Very low certainty.
• Size: 5 randomised controlled trials.
• Who: people receiving palliative care with constipation.
• How long: searches to September 2014; trial durations not stated in the abstract.
• Result: no meta-analysis was possible because every study compared different laxatives or combinations; the review states there was no evidence on whether individual laxatives were more effective than others or caused fewer adverse effects; the authors add that extrapolating effectiveness findings from other populations should proceed with caution because differences inherent in people receiving palliative care may act, in a likely negative way, on the effect of a laxative.
• Funding: Cochrane review; funding not stated in the abstract.

Limit of this finding: Five small trials, all at an unclear risk of bias, with no two comparing the same agents, so this is an absence of comparative evidence rather than a demonstration that the laxatives are equivalent. The authors specifically warn that evidence from non-palliative populations may overstate how well a laxative works in palliative care.

As all five studies compared different laxatives or combinations of laxatives, it was not possible to perform a meta-analysis. There was no evidence on whether individual laxatives were more effective than others or caused fewer adverse effects. AUTHORS' CONCLUSIONS: This second update found that laxatives were of similar effectiveness but the evidence remains limited due to insufficient data from a few small RCTs.

A systematic review that set out to compare docusate, sennosides and lactulose against polyethylene glycol in opioid-induced constipation found no studies at all that met its inclusion criteria, so it reports no efficacy or safety comparison. (Source 5)

• Systematic review, Very low certainty.
• Size: no studies met inclusion criteria.
• Who: adults taking opioids for cancer or non-cancer pain.
• How long: not applicable.
• Result: statistical pooling was not possible; the review reports zero eligible randomised trials.
• Funding: not stated in the abstract.

Limit of this finding: This source contains no evidence either way: no trial met the review's inclusion criteria, so statistical pooling was not possible and the review reports no result. It must not be read as support for docusate, sennosides or lactulose, and equally it is not a demonstration that they fail in opioid-induced constipation - it is an absence of trials. The review is a nursing-journal systematic review with no pooled data and no numbers of any kind.

Statistical pooling was not possible as no studies met inclusion criteria. Large, well-powered, randomized controlled trials are feasible. Standard definitions of OIC would assist with the execution of these studies and contribute to their internal and external validity. Further research is strongly encouraged.

Long-term anthranoid laxative use and melanosis coli were not associated with any increased risk of colorectal adenoma or carcinoma. (Source 22)

• Case-control study, Low certainty.
• Size: 202 patients with newly diagnosed colorectal carcinoma, 114 with adenomatous polyps, 238 controls with no neoplasm.
• Who: people referred for total colonoscopy at the University of Erlangen.
• How long: use assessed by standardised interview, including long-term use; no difference between groups in duration of intake.
• Result: unadjusted odds ratio 1.0 (95% CI 0.5-1.9) for adenomas and 1.0 (95% CI 0.6-1.8) for carcinomas; after adjustment for age, sex and blood in the stools, 0.84 (95% CI 0.4-1.7) for adenomas and 0.93 (95% CI 0.5-1.7) for carcinomas.
• Funding: not stated in the abstract.

Limit of this finding: A case-control study relying on interview recall of laxative use, from a single centre; the confidence intervals are wide enough to be compatible with a modest risk in either direction. The abstract prints the adjusted odds ratio for adenomas with a stray space inside its lower bound - "0.84 (95% CI 0. 4-1.7)" - which is the source's own typography and is quoted unaltered; read it as 0.4 to 1.7. This is a reassuring null result from interview-recalled laxative use at a single centre, not a demonstration of safety.

There was no statistically significant risk of anthranoid use for the development of colorectal adenomas (unadjusted odds ratio 1.0; 95% CI 0.5-1.9) or carcinomas (unadjusted odds ratio 1.0; 95% CI 0.6-1.8). Even after adjustment for the risk factors age, sex, and blood in the stools by logistic regression analysis the odds ratio for adenomas was 0.84 (95% CI 0. 4-1.7) and for carcinomas 0.93 (95% CI 0.5-1.7).

Stimulant laxatives are not addictive, do not cause rebound constipation when stopped, and tolerance to them is uncommon. (Source 12)

• Expert review, not systematic, Low certainty.
• Size: not stated; a review of strongly held beliefs about constipation with no stated search method.
• Who: people with chronic constipation.
• How long: not applicable.
• Result: no effect sizes; the review states that tolerance is uncommon, that there is no indication of rebound constipation after stopping, and that there is no potential for addiction.
• Funding: not stated in the abstract.

Limit of this finding: This is an expert narrative review with no stated method, so its statements are assertions supported by cited literature rather than a systematic appraisal. It is the clearest published refutation of the habit-forming belief, but it is not a systematic review.

A proportion of patients with chronic constipation is dependent of laxatives to achieve satisfactory bowel function, but this is not the result of prior laxative intake. Tolerance to stimulant laxatives is uncommon. There is no indication for the occurrence of "rebound constipation" after stopping laxative intake. While laxatives may be misused, there is no potential for addiction.

There is no good evidence that stimulant laxatives, senna included, structurally damage the colon or its nerves at recommended doses, and cathartic colon is now regarded as a historical entity. (Source 23)

• Systematic review, Low certainty.
• Size: 43 publications identified and reviewed from PubMed and Embase searches to June 2023.
• Who: people and animals exposed to bisacodyl, sodium picosulfate and senna, including long-term and high-dose users.
• How long: literature spanning from a 1968 case report onwards.
• Result: no pooled effect size; the review states that no well-controlled prospective clinical studies have demonstrated such changes in humans, and that reports of cathartic colon all concern patients who began taking laxatives between 1910 and 1960, with no published cases since 1960.
• Funding: Industry-involved: Sanofi provided financial support for publication costs and medical writing, one author is a Sanofi employee who may hold Sanofi stock, and the lead author has consulted for or received research funding from Sanofi among others. Sanofi markets stimulant laxatives.

Limit of this finding: The quoted sentence names bisacodyl and sodium picosulfate, the sponsor's products, and not senna, even though the review's scope includes senna; the generalisation to senna in the following sentence is the authors' own. Given the funding, the direction of this review's conclusions should be read with that in mind. The same conclusion records one exception: carcinogenic potential was demonstrated for phenolphthalein, an older stimulant laxative, at chronic high doses in animal studies, which is why it was withdrawn - though the review says this was never demonstrated in humans. The flattened digits in the quoted text are reference numbers, not figures.

However, no well-controlled prospective clinical studies have demonstrated any such changes associated with the administration of diphenyl-methane laxatives, bisacodyl, or SPS in humans. It remains unclear from uncontrolled studies whether the reported changes were attributable to an underlying disease, the primary motility disorder itself, or if the cause was chronic use of laxatives. Thus, there is no good evidence that stimulant laxatives cause structural impairment of enteric nerves or intestinal smooth muscle when used at recommended therapeutic doses.

The same Cochrane review concluded there is insufficient evidence to assess the effectiveness and safety of treatments for constipation in pregnancy, and described the stimulant-laxative result as accompanied by an increase in diarrhoea. (Source 24)

• Systematic review, Low certainty.
• Size: 4 studies included, only 2 contributing data, 180 women in total.
• Who: pregnant women with constipation.
• How long: not stated in the abstract.
• Result: no new numbers; the authors state the limitation as few studies with small sample size and no meta-analyses, and summarise the stimulant-versus-bulk-forming comparison as more effective for constipation (moderate quality evidence) but accompanied by an increase in diarrhoea (moderate quality evidence) and abdominal discomfort (low quality evidence), with no difference in women's satisfaction.
• Funding: Cochrane review; funding not stated in the abstract.

Limit of this finding: The same review's results section calls the diarrhoea result a "borderline difference" with a confidence interval of 1.01 to 20.09, while this conclusion calls it "an increase". Both readings come from one estimate in one study of 140 women, so neither the benefit nor the harm is established.

There is insufficient evidence to comprehensively assess the effectiveness and safety of interventions (pharmacological and non-pharmacological) for treating constipation in pregnancy, due to limited data (few studies with small sample size and no meta-analyses).

Where the evidence is mixed

A retrospective study reported bowel movements in two thirds of hospitalised children given oral docusate and claimed this proves efficacy, which its design cannot support. (Source 25)

• Cohort study, Very low certainty.
• Size: 90 patients in each of the docusate and polyethylene glycol groups.
• Who: hospitalised children aged 1 month to 18 years receiving oral docusate or PEG-3350, with prior laxative use and several chronic conditions excluded.
• How long: first 72 hours of drug administration.
• Result: bowel movement within 72 h in 66.67% on docusate and 71.11% on PEG-3350, p = 0.5196; time to first bowel movement 48.9 h versus 45.4 h, p = 0.3283; no differences in adverse effects or acceptance.
• Funding: not stated in the abstract.

Limit of this finding: The abstract claims the study 'proves the efficacy of oral docusate' but it is retrospective with no placebo or no-treatment arm, so the 66.67% figure cannot be separated from spontaneous recovery. A reader should treat this as a null comparison against polyethylene glycol, not as evidence that docusate works.

Bowel movements occurred within 72 h in 66.67% in the docusate group and 71.11% in the PEG-3350 group. There was no significant difference between the groups (p = 0.5196). The time to achieve first bowel movement was not different between groups (48.9 h vs. 45.4 h, docusate and PEG-3350, p = 0.3283). There were no differences in adverse effects or acceptance between groups. CONCLUSIONS: This is the first study that proves the efficacy of oral docusate in the treatment of hospitalized pediatric patients with acute constipation. It is also the first study that shows no difference in efficacy between docusate and PEG-3350 in pediatric patients. We hope a prospective trial would further confirm our findings.

Where the research disagrees

Whether docusate works at all

• Nguyen and colleagues, review of randomised trials in older people, 2021, narrative review of four randomised trials in older adults, single-database search, no meta-analysis and no pooled estimate: Docusate when compared with placebo or psyllium or sennosides in these trials did not show any benefits for constipation. Psyllium and sennosides showed to be more effective compared with docusate. (Source 6)
• Tarumi and colleagues, double-blind placebo-controlled trial, 2013, 10-day double-blind randomised placebo-controlled trial in 74 hospice patients: There was no significant benefit of docusate plus sennosides compared with placebo plus sennosides in managing constipation in hospice patients. (Source 21)
• Saif and colleagues, retrospective study in children, 2025, retrospective multicentre record review of 180 hospitalised children, no placebo arm: This is the first study that proves the efficacy of oral docusate in the treatment of hospitalized pediatric patients with acute constipation. (Source 25)
• Saif and colleagues, in their own introduction, on the evidence before their study, 2025, the authors’ summary of prior evidence, citing their references (9, 10) and (11): In adult patients, docusate's efficacy has been called into question (9, 10). This evidence has not been duplicated in pediatric patients (11). (Source 26)
• The Colace Clear Drug Facts panel, 2026, regulator-approved over-the-counter monograph position, no trial data on the panel: Active ingredient Purpose (in each soft gel) Docusate sodium 50 mg........... Stool softener (Source 27)

Whether long-term stimulant laxative use harms the colon

• Whorwell, Lange and Scarpignato, Sanofi-supported review, 2024, review of 43 publications; Sanofi funded publication costs and medical writing and one author is a Sanofi employee: Thus, there is no good evidence that stimulant laxatives cause structural impairment of enteric nerves or intestinal smooth muscle when used at recommended therapeutic doses. (Source 23)
• The older clinical literature the same review summarises, small retrospective studies of 29 and 35 long-term, often very high-dose users, with concomitant disease not reported: Approximately half (45%) of the patients showed radiographically documented anatomical changes of colonic redundancy and dilation of colon, with loss of haustral markings (Source 13)
• Nusko and colleagues, prospective case-control study, 2000, case-control study of 554 people referred for total colonoscopy, cancer and adenoma outcomes: Neither anthranoid laxative use, even in the long term, nor macroscopic or marked microscopic melanosis coli were associated with any significant risk for the development of colorectal adenoma or carcinoma. (Source 22)

How much

• Reference intake: No dose is given here for a reader. As a position, the Drug Facts panel of the fixed combination states the strengths as docusate sodium 50mg and sennosides 8.6mg per tablet. (Source 2)
• Upper limit: The senna label’s own limit is on duration rather than amount for the user: its "Do not use" panel says not to use laxative products for longer than 1 week unless directed by a doctor. (Source 18)
• Studied: The placebo-controlled chronic constipation trial gave senna 1.0 g, magnesium oxide 1.5 g, or placebo for 28 consecutive days. (Source 3)
• Studied: The hospice trial compared docusate plus sennosides against placebo plus sennosides over 10 days in 74 patients. (Source 21)
• Studied: The Drug Facts Directions table for senna with docusate sets out starting and maximum tablet counts by age band, and states 'ask a doctor' for children under 2 years. (Source 11)

A common belief, and what the research shows

The belief: Laxatives like senna are habit-forming: use them for long and your bowel stops working on its own, so you have to wean off them.

What the research shows: The literature says the opposite on every part of this. On dependence: A proportion of patients with chronic constipation is dependent of laxatives to achieve satisfactory bowel function, but this is not the result of prior laxative intake. On tolerance and rebound: Tolerance to stimulant laxatives is uncommon. There is no indication for the occurrence of "rebound constipation" after stopping laxative intake. While laxatives may be misused, there is no potential for addiction. And on the colon wearing out, a 2024 review of 43 publications found no well-controlled prospective clinical studies have demonstrated any such changes associated with the administration of diphenyl-methane laxatives, bisacodyl, or SPS in humans. The real reason the labels cap use at one week is different: persistent constipation or rectal bleeding may point to a condition that needs diagnosing. The separate and better-supported misconception to correct is about docusate, the softener half of this combination, which the randomised trials do not show to work.

Questions and answers

What is it?

It is one tablet containing two laxatives: sennosides, the active glycosides of the senna plant, and docusate sodium, a surfactant stool softener. The common over-the-counter strength is docusate sodium 50mg with sennosides 8.6mg per tablet. Each is also sold on its own, as senna tablets and as docusate capsules. (Source 2)

What does it do in the body?

The senna half stimulates the bowel: stimulant laxatives act by increasing intestinal motility and secretion through a local effect on the nerve plexus and smooth muscle of the intestine. The docusate half is a detergent that lowers the surface tension at the water-oil interface of the stool so water and fat mix in, softening it. In practice the combination product tells users to expect a bowel movement in 6 to 12 hours, which is senna's timescale. (Source 1)

Is it good or bad for you?

Mostly good for short-term occasional constipation, and the good comes from the senna. A randomised placebo-controlled trial found overall improvement in 69.2% on senna against 11.7% on placebo. The docusate half has no demonstrated benefit over placebo. Harms at labelled use are minor; the serious harms in the literature, low potassium with cardiac effects, come from misuse, abuse or much higher doses, and melanosis coli follows long use and reverses. It becomes the wrong choice when constipation lasts beyond a week, which is a reason to be assessed rather than to keep taking it. (Source 3)

How do you get more of it?

Both components are over-the-counter products, sold as the fixed combination and separately. Nothing needs to be done to get more of them in the body, and the labels put a ceiling on use rather than a floor: not longer than one week without medical direction. There is no reason to seek a higher exposure, and in the trials the studied amounts were senna 1.0 g daily for 28 days in chronic constipation, or the age-banded tablet counts on the Drug Facts panel. (Source 3)

If it is harmful, what reduces it?

Stopping is all that is needed, and there is no taper: tolerance is uncommon and there is no indication of rebound constipation after stopping. Melanosis coli, the one visible change, cleared on colonoscopy seven months after one patient stopped senna. If low potassium has developed it is corrected medically, and the labels name rectal bleeding or no bowel movement after a laxative as reasons to stop and see a doctor. (Source 12)

Why might someone be low in it or missing it?

Neither is a nutrient, so nobody can be deficient in them. The question that matters instead is why someone becomes constipated, and the literature is blunt that most of the usual explanations are wrong: a low-fibre diet should not be assumed to be the cause, increasing fluid intake does not treat constipation unless the person is dehydrated, and hypothyroidism is rare among people presenting with constipation. Opioids, immobility and other medicines are real causes. (Source 28)

Which whole foods contain it or feed it?

Senna comes from a plant, Senna alexandrina, but it is not a food: the leaves and pods are used as a herbal preparation and as the standardised pharmaceutical extract, not eaten as a vegetable. Docusate is wholly synthetic and occurs in no food. The food-level intervention studied alongside senna is fibre, specifically Plantago ovata (psyllium), which appeared both combined with senna and as a comparator that outperformed docusate. (Source 7)

What happens if you do not have it?

Not taking it means untreated constipation, which in the placebo arm of the chronic constipation trial meant overall improvement in only 11.7% of people over 28 days. Constipation itself is not harmless: one review notes evidence that constipation may be associated with colorectal cancer and that the risk rose with its severity, which is part of why withholding treatment is not the safe default. (Source 23)

How can you test for it?

There is no blood test for either component and no reason to measure them. What gets measured is the outcome and the complications: stool frequency and consistency, often on the Bristol Stool Form Scale, as in the hospice trial; blood potassium if misuse or cardiac symptoms are suspected; and colonoscopy, which both diagnoses melanosis coli and looks for the serious causes that the labels' stop-use warnings point at. Stool diaries and symptom scores are self-reported and so vary with how they are collected. (Source 21)

References

1. Therapeutic Advances in Gastroenterology. Review article: do stimulant laxatives damage the gut? A critical analysis of current knowledge - Introduction. 2024. PMID 38887508, DOI 10.1177/17562848241249664. Read the source
2. DailyMed / US FDA Structured Product Label (Atlantis Consumer Healthcare, Inc.). SENOKOT-S (standardized senna concentrate and docusate sodium) tablet - OTC Drug Facts, Active ingredients section. 2026. Read the source
3. The American journal of gastroenterology. Senna Versus Magnesium Oxide for the Treatment of Chronic Constipation: A Randomized, Placebo-Controlled Trial.. 2021. PMID 32969946, DOI 10.14309/ajg.0000000000000942. Read the source
4. The Cochrane database of systematic reviews. Laxatives for the management of constipation in people receiving palliative care.. 2015. PMID 25967924, DOI 10.1002/14651858.CD003448.pub4. Read the source
5. Canadian oncology nursing journal = Revue canadienne de nursing oncologique. Efficacy and side-effect profiles of lactulose, docusate sodium, and sennosides compared to PEG in opioid-induced constipation: a systematic review.. 2013. PMID 24428006, DOI 10.5737/1181912x234236240. Read the source
6. The Senior care pharmacist. The Role of Docusate for Constipation in Older People.. 2021. PMID 34593092, DOI 10.4140/TCP.n.2021.501. Read the source
7. Journal of clinical pharmacy and therapeutics. Efficacy and safety of laxatives for chronic constipation in long-term care settings: A systematic review.. 2018. PMID 29885259, DOI 10.1111/jcpt.12721. Read the source
8. The Cochrane database of systematic reviews. Interventions for treating constipation in pregnancy.. 2015. PMID 26342714, DOI 10.1002/14651858.CD011448.pub2. Read the source
9. DailyMed / US FDA Structured Product Label (Atlantis Consumer Healthcare, Inc.). COLACE Clear (docusate sodium 50 mg dye-free soft gel) - OTC Drug Facts, "Do not use" section (LOINC 50570-1); this section carries the panel's "Warnings" heading but only the mineral-oil bullet - the rest of the Warnings panel is in dailymed-colace-ask-a-doctor, dailymed-colace-stop-use, dailymed-colace-pregnancy and dailymed-colace-keep-out-of-reach. 2026. Read the source
10. Journal of clinical pharmacy and therapeutics. Adverse drug event of hypokalaemia-induced cardiotoxicity secondary to the use of laxatives: A systematic review of case reports.. 2020. PMID 32672366, DOI 10.1111/jcpt.13204. Read the source
11. DailyMed / US FDA Structured Product Label (A-S Medication Solutions). SENOKOT (standardized senna) tablet - OTC Drug Facts, Directions section with the full age table. 2026. Read the source
12. The American journal of gastroenterology. Myths and misconceptions about chronic constipation.. 2005. PMID 15654804, DOI 10.1111/j.1572-0241.2005.40885.x. Read the source
13. Therapeutic Advances in Gastroenterology. Review article: do stimulant laxatives damage the gut? A critical analysis of current knowledge - clinical studies on cathartic colon. 2024. PMID 38887508, DOI 10.1177/17562848241249664. Read the source
14. International medical case reports journal. Colonoscopic Resolution of Melanosis Coli After Cessation of Senna Laxative Use.. 2024. PMID 39282237, DOI 10.2147/IMCRJ.S475869. Read the source
15. DailyMed / US FDA Structured Product Label (Atlantis Consumer Healthcare, Inc.). COLACE Clear (docusate sodium 50 mg dye-free soft gel) - OTC Drug Facts, "Stop use and ask a doctor if" section (LOINC 50566-9). 2026. Read the source
16. DailyMed / US FDA Structured Product Label (Atlantis Consumer Healthcare, Inc.). COLACE Clear (docusate sodium 50 mg dye-free soft gel) - OTC Drug Facts, "Keep out of reach of children" and overdose section (LOINC 50565-1). 2026. Read the source
17. Acta gastro-enterologica Belgica. Subacute cholestatic hepatitis likely related to the use of senna for chronic constipation.. 2005. PMID 16268429. Read the source
18. DailyMed / US FDA Structured Product Label (A-S Medication Solutions). SENOKOT (standardized senna) tablet - OTC Drug Facts, Do not use section. 2026. Read the source
19. DailyMed / US FDA Structured Product Label (Atlantis Consumer Healthcare, Inc.). COLACE Clear (docusate sodium 50 mg dye-free soft gel) - OTC Drug Facts, "Ask a doctor before use if you have" section (LOINC 50569-3). 2026. Read the source
20. Canadian journal of gastroenterology & hepatology. Systematic review of stimulant and nonstimulant laxatives for the treatment of functional constipation.. 2014. PMID 25390617, DOI 10.1155/2014/631740. Read the source
21. Journal of pain and symptom management. Randomized, double-blind, placebo-controlled trial of oral docusate in the management of constipation in hospice patients.. 2013. PMID 22889861, DOI 10.1016/j.jpainsymman.2012.02.008. Read the source
22. Gut. Anthranoid laxative use is not a risk factor for colorectal neoplasia: results of a prospective case control study.. 2000. PMID 10764708, DOI 10.1136/gut.46.5.651. Read the source
23. Therapeutic Advances in Gastroenterology. Review article: do stimulant laxatives damage the gut? A critical analysis of current knowledge - Conclusion. 2024. PMID 38887508, DOI 10.1177/17562848241249664. Read the source
24. Cochrane Database of Systematic Reviews. Interventions for treating constipation in pregnancy - Cochrane Database of Systematic Reviews, Authors' conclusions. 2015. PMID 26342714, DOI 10.1002/14651858.CD011448.pub2. Read the source
25. Frontiers in pediatrics. Efficacy of docusate in the treatment of constipation in pediatric patients.. 2025. PMID 41141999, DOI 10.3389/fped.2025.1652620. Read the source
26. Frontiers in Pediatrics. Efficacy of docusate in the treatment of constipation in pediatric patients - Introduction, prior evidence on docusate. 2025. PMID 41141999, DOI 10.3389/fped.2025.1652620. Read the source
27. DailyMed / US FDA Structured Product Label (Atlantis Consumer Healthcare, Inc.). COLACE Clear (docusate sodium 50 mg dye-free soft gel) - OTC Drug Facts, Active ingredient / Purpose table (LOINC 55105-1). 2026. Read the source
28. The American journal of gastroenterology. Myths and misconceptions about chronic constipation.. 2005. PMID 15654804, DOI 10.1111/j.1572-0241.2005.40885.x. Read the source